US 11390884
Optimized CRISPR/cas9 systems and methods for gene editing in stem cells
granted A61KA61K35/28A61K35/545
Quick answer
US patent 11390884 (Optimized CRISPR/cas9 systems and methods for gene editing in stem cells) held by Editas Medicine, Inc. expires Mon Jul 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Editas Medicine, Inc.
- Grant date
- Tue Jul 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jul 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 16
- CPC classes
- A61K, A61K35/28, A61K35/545, A61K40/10, A61K40/46